TMT-MS3-Enabled proteomic quantification of human IPSC-Derived neurons

Abstract

The induced pluripotent stem cell (IPSC)-derived neurons technology has matured to a point where neurological disorders such as autism, schizophrenia, Alzheimer’s, and Parkinson’s disease can be reproducibly modeled. Proteomic analysis of these model systems has the potential to identify disease signatures, characterize treatment effects, and drive biomarker identification. Here we describe the implementation of a TMT-MS3-based proteomic workflow for the characterization of over 7000 proteins in whole cell lysates obtained from human IPSC-derived neurons. This multiplexing protocol should have a better reproducibility and higher number of assessed conditions than the label-free or SILAC-based proteomics approaches.